Related Experiment Video

Updated: May 22, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Neonatal fungal infections: when to treat?

E Hsieh1, P B Smith, E Jacqz-Aigrain

  • 1Duke-National University of Singapore Graduate Medical School, Singapore.

Early Human Development
|May 29, 2012
PubMed

Insights

Candida infections pose significant risks in neonatal intensive care units. Early antifungal therapy is crucial for high-risk infants unresponsive to antibiotics, especially those with specific risk factors.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Mycology

Background:

  • Neonatal intensive care units (NICUs) face significant challenges with Candida infections.
  • These infections contribute to substantial morbidity and mortality in vulnerable infants.
  • Mortality from Candida bloodstream infections can reach 40%, with survivors often experiencing neurodevelopmental impairment.

Purpose of the Study:

  • To highlight the critical need for considering empirical antifungal therapy in high-risk neonates.
  • To provide guidance on identifying infants who may benefit from early antifungal intervention.
  • To emphasize the diagnostic challenges of invasive fungal infections in neonates.

Main Methods:

  • Review of clinical data and risk factors associated with Candida infections in NICU settings.
  • Analysis of outcomes for infants with invasive fungal infections.
  • Evaluation of treatment strategies, including empirical antifungal therapy.

Main Results:

  • Invasive fungal infections, particularly Candida, are difficult to diagnose promptly.
  • Empirical antifungal therapy should be considered for neonates failing to respond to antibacterial treatments.
  • Key risk factors include extreme prematurity, central venous catheter use, and prior exposure to third-generation cephalosporins.

Conclusions:

  • Prompt recognition and treatment of Candida infections are vital in NICU settings.
  • Empirical antifungal therapy is a necessary consideration for high-risk neonates.
  • Identifying and managing risk factors can improve outcomes for invasive fungal infections in premature infants.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Related Concept Videos

Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...